2016
Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance
Ly TT, Weinzimer SA, Maahs DM, Sherr JL, Roy A, Grosman B, Cantwell M, Kurtz N, Carria L, Messer L, von Eyben R, Buckingham BA. Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes 2016, 18: 348-355. PMID: 27191182, DOI: 10.1111/pedi.12399.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdolescentAdolescent BehaviorAdultAlgorithmsBlood GlucoseBlood Glucose Self-MonitoringCalibrationCohort StudiesDiabetes Mellitus, Type 1Drug Dosage CalculationsDrug MonitoringGlucoseHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinPancreas, ArtificialPrecision MedicineSubcutaneous TissueYoung AdultConceptsType 1 diabetesAdolescent cohortAdult cohortHybrid closed-loop systemPump therapyPercentage of timeGlucose valuesSensor-augmented pump therapyOverall glucose controlInsulin pump therapyOverall mean percentageDose insulinGlucose controlPreliminary safetyInsulin delivery systemsInitial cohortHybrid closed-loop controlClinical practiceSecond cohortCohortMean percentageTarget rangeOverall percentageDiabetesAdults
2013
The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*
Buckingham B, Beck R, Ruedy K, Cheng P, Kollman C, Weinzimer S, DiMeglio L, Bremer A, Slover R, Cantwell M. The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*. Diabetes Technology & Therapeutics 2013, 15: 401-408. PMID: 23570538, PMCID: PMC3643224, DOI: 10.1089/dia.2013.0002.Peer-Reviewed Original ResearchConceptsType 1 diabetesMean glucose concentrationHybrid closed-loop controlMedian percentageHybrid closed-loop therapyType 1Sensor-augmented pump therapyPositive pancreatic autoantibodiesTrialNet Study GroupDays of diagnosisNormal glycemic controlΒ-cell functionGlucose concentrationClosed-loop therapyPancreatic autoantibodiesGlycemic controlSAP therapyPump therapyStudy groupGlucose levelsGlucose toxicityDay 2Day 3Glucose valuesTherapy
2008
Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas
Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas. Diabetes Care 2008, 31: 934-939. PMID: 18252903, DOI: 10.2337/dc07-1967.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose levelsHCl groupFCL groupInsulin pumpBeta cell replacement therapyPostprandial glycemic excursionsPostprandial glucose excursionsPostprandial glucose levelsClosed-loop glucose controlArtificial pancreasClosed-loop artificial pancreasPediatric patientsPostprandial excursionsBolus dosesGlycemic excursionsReplacement therapySubcutaneous routeGlucose controlGlucose excursionsInsulin delivery systemsHybrid closed-loop controlInsulin absorptionType 1Dl